Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Item

http://www.wikidata.org/entity/Q33956698

Q33956698

about

A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure Clinical adoption of prognostic biomarkers: the case for heart failure Natriuretic peptide testing for predicting adverse events following heart failure hospitalization Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.Prevalence and treatment of heart failure in Swedish nursing homes B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes.Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology De novo acute heart failure and acutely decompensated chronic heart failure Long-term mortality in older patients discharged after acute decompensated heart failure: a prospective cohort study.Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure.Diagnostic values of NT-proBNP in acute dyspnea among elderly patients.Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography Depression and Multiple Rehospitalizations in Patients With Heart Failure.Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF Worse Prognosis in Heart Failure Patients with 30-Day Readmission.Diagnosis and management of acute heart failure The role of natriuretic peptides: from the emergency department throughout hospitalization.The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.Heart failure biomarkers at point-of-care: current utilization and future potential.Hospital readmission in heart failure, a novel analysis of a longstanding problem.Biomarkers in hypertension and their relationship with myocardial target-organ damage.Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure.Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Stud The use of discharge haemoglobin and NT-proBNP to improve short and long-term outcome prediction in patients with acute heart failure.Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial.Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.An Admission-to-Discharge BNP Increase Is a Predictor of Six-Month All-Cause Death in ADHF Patients: Inferences from Multivariate Analysis Including Admission BNP and Various Clinical Measures of Congestion Major Depression and Long-Term Survival of Patients With Heart Failure.Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function.Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial.A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress.Ultrafiltration versus intravenous loop diuretics in patients with acute decompensated heart failure: a meta-analysis of clinical trials.

P2860

Q26770151-9F18599D-16C0-466D-A209-AD17A875971E Q26863716-F9B9DA96-6230-42B2-BE01-F672F0A0A26D Q27008553-8B5057A0-1B16-4545-9B00-59CEA033BDEE Q30413291-FDD94A2B-94BD-4F23-98DC-CE8D1C3F9699 Q33857564-895FFC71-BB08-423E-9F25-1CFB67CB306B Q34492442-95F11806-0388-4235-B9AA-2D67ABC43373 Q35021886-DC2E005A-049F-4999-8A22-4F4CF11CA2F9 Q35077700-151B2665-344B-40CC-87A7-0F68F675ADC7 Q35675983-19169971-CCEA-49A9-A32E-D86CCB69941C Q36261618-25EDD5D5-0082-4BDF-B54E-419B5695236E Q36306272-D342376F-DEA5-4CDC-B71E-5B4E926F3207 Q36375532-70939929-1F67-49BC-B311-B5262682422A Q36787107-A0A22E47-5C22-47A1-B94E-748ABB8E4CEC Q36932609-A3D210A9-F249-4CE0-9BC2-A62AB5DE611F Q37206133-E746EEC9-068B-40D9-9595-8C50C6C99305 Q37240303-A7503FFC-0B8F-4052-837D-D011AF347157 Q37448659-CDA4AB44-8A29-4E8C-BFD6-C5BA75040C62 Q37680530-29CF71CD-7D48-448C-96E0-DB0C917A63AE Q38034549-BE73D198-7625-4256-B62F-52BB3603EA72 Q38063118-AFF64970-D9F4-4E98-8D42-E25B3B405510 Q38187750-C983F990-F763-4D5D-A482-2977834AEEC2 Q38257320-E3277744-CDE7-46FF-A8F8-4379F7D84E5F Q38258970-6B093115-283A-4237-AA33-6D75DE7439FE Q38642916-AB756298-B3A5-493E-9A9D-C433AE84540A Q38906411-E894B9C0-2AAD-4E73-A130-9F424863E996 Q39010655-452E2B59-559D-4F5B-8B74-C33A03D46083 Q39012314-FA5EE68D-ED92-4ADB-A1A1-EF17A154FF54 Q39055218-44C53E13-E5CF-4DFF-988B-C27F97E88D24 Q39127729-7020834B-D393-4D83-AC4C-74C76F90B191 Q39195887-C4225BD0-4F45-4A57-86F0-A9585FDE3460 Q39760017-D4524B6F-9A45-4331-8ADE-32E2A924B3E5 Q39806082-530A3859-3F80-426E-BD3F-C56F3B13B486 Q40116429-237DAE44-4395-4752-9A3F-3E7B8598488E Q40359671-7D033E46-B798-4B62-9A91-DF849A4D5684 Q41104192-9958C78F-11AE-4E5C-8DB4-646770011C2F Q41534613-E42ABA13-E236-4E0A-9E07-25E4BDCA8202 Q44165489-7AE3C12F-3B7B-4A1D-8659-BBBF210E5771 Q45091868-F2223A51-C25F-49F0-B781-2CCF2671B985 Q46308133-7A5F09D7-EC62-4340-9B56-2DCE5C95CE1A Q47861853-DFC97CB3-E409-4535-960D-D81EB7B54C7D

P2860

Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.

Item

http://www.wikidata.org/entity/Q33956698

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu